Annual Total Long Term Liabilities
$125.69 M
+$65.09 M+107.41%
December 31, 2021
Summary
- As of February 10, 2025, PHAS annual total long term liabilities is $125.69 million, with the most recent change of +$65.09 million (+107.41%) on December 31, 2021.
- During the last 3 years, PHAS annual total long term liabilities has risen by +$118.17 million (+1570.98%).
Performance
PHAS Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Long Term Liabilities
$114.89 M
-$4.49 M-3.76%
June 30, 2022
Summary
- As of February 10, 2025, PHAS quarterly total long term liabilities is $114.89 million, with the most recent change of -$4.49 million (-3.76%) on June 30, 2022.
- Over the past year, PHAS quarterly long term liabilities has increased by +$11.25 million (+10.85%).
Performance
PHAS Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
PHAS Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +107.4% | +10.8% |
| 3 y3 years | +1571.0% | +1039.4% |
| 5 y5 years | +33.8% | - |
PHAS Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | at low | -8.6% | at low |
| 5 y | 5-year | at high | -88.8% | -8.6% | -87.8% |
| alltime | all time | at high | -94.0% | -15.5% | -96.4% |
PhaseBio Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $114.89 M(-3.8%) |
| Mar 2022 | - | $119.37 M(-5.0%) |
| Dec 2021 | $125.69 M(+107.4%) | $125.69 M(+17.9%) |
| Sep 2021 | - | $106.60 M(+2.9%) |
| Jun 2021 | - | $103.64 M(+36.8%) |
| Mar 2021 | - | $75.74 M(+25.0%) |
| Dec 2020 | $60.60 M | $60.60 M(+42.6%) |
| Sep 2020 | - | $42.48 M(+59.6%) |
| Jun 2020 | - | $26.61 M(+67.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $15.88 M(+13.1%) |
| Dec 2019 | $14.04 M(+86.6%) | $14.04 M(+48.7%) |
| Sep 2019 | - | $9.44 M(-6.4%) |
| Jun 2019 | - | $10.08 M(+18.5%) |
| Mar 2019 | - | $8.51 M(+13.1%) |
| Dec 2018 | $7.52 M(-92.0%) | $7.52 M(-94.5%) |
| Sep 2018 | - | $135.97 M(+3192.3%) |
| Jun 2018 | - | $4.13 M(-95.6%) |
| Dec 2017 | $93.92 M(+3.8%) | $93.92 M |
| Dec 2016 | $90.45 M | - |
FAQ
- What is PhaseBio Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for PhaseBio Pharmaceuticals?
- What is PhaseBio Pharmaceuticals annual total long term liabilities year-on-year change?
- What is PhaseBio Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for PhaseBio Pharmaceuticals?
- What is PhaseBio Pharmaceuticals quarterly long term liabilities year-on-year change?
What is PhaseBio Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of PHAS is $125.69 M
What is the all time high annual total long term liabilities for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals all-time high annual total long term liabilities is $125.69 M
What is PhaseBio Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, PHAS annual total long term liabilities has changed by +$65.09 M (+107.41%)
What is PhaseBio Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of PHAS is $114.89 M
What is the all time high quarterly long term liabilities for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals all-time high quarterly total long term liabilities is $135.97 M
What is PhaseBio Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, PHAS quarterly total long term liabilities has changed by +$11.25 M (+10.85%)